Oryzon Genomics: Developing treatments for the underlying causes of cancer and CNS diseases by targeting lysine specific demethylase 1 (LSD1, aka KDM1A), an epigenetic histone modifying enzyme. Lead CNS compound ORY-2001 is now in three Phase IIa trials in MS, AD and in a basket trial in aggression. Oncology compound, ORY-1001, is in two combo Phase IIa trials in AML and SCLC. Expected data in mid 2019. Oryzon is one of the most liquid small-cap stocks in the Spanish Main market.
Based in...
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Central Nervous System, Oncology
Pre-earnings, Revenues
Europe, Public
Market Cap
100MM - 500MM
Therapeutic Modalities
Gene Therapy, Platform Technology, Small Molecule
08940 Cornellà de Llobregat

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout Clients at Jefferies

New York, NY, United States, June 4 – June 7, 2019

European Biotech Investor Day 2019

New York City, August 1, 2019

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.